Adimmune Corporation

Taiwan Stock Exchange 4142.TW

Adimmune Corporation Market Capitalization on January 14, 2025: USD 296.80 M

Adimmune Corporation Market Capitalization is USD 296.80 M on January 14, 2025, a -30.60% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Adimmune Corporation 52-week high Market Capitalization is USD 427.70 M on January 15, 2024, which is 44.10% above the current Market Capitalization.
Adimmune Corporation 52-week low Market Capitalization is USD 235.46 M on January 07, 2025, which is -20.67% below the current Market Capitalization.
Adimmune Corporation average Market Capitalization for the last 52 weeks is USD 345.83 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

Taiwan Stock Exchange: 4142.TW

Adimmune Corporation

CEO	Mr. Chi-Hsien Chan
IPO Date	May 3, 2012
Location	Taiwan
Headquarters	No. 3, Tanxing Road
Employees	564
Sector	Health Care
Industries Vaccines Pharmaceuticals

Description

Adimmune Corporation manufactures and sells human vaccines in Taiwan. It offers AdimFlu-S, a quadrivalent influenza vaccine; tetanus toxoid alum precipitated product that is used for the prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent influenza vaccines; Quadrivalent influenza vaccine; Influenza A (H1N1) Virus Monovalent Vaccine; Tetanus Toxoid; and purified Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was founded in 1965 and is headquartered in Taichung, Taiwan.

Key trends

Past 5 years